NCT07632300 Apply Biphasic IVM for POSEIDON Group 1
| NCT ID | NCT07632300 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mỹ Đức Hospital |
| Condition | Healthy Adult Females |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2026-06-12 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 25 participants in total. It began in 2026-06-12 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if biphasic In Vitro Maturation (IVM) works to help young women who produce very few oocytes after controlled ovarian stimulation. The study focuses on women under age 35 who have a good number of follicles in their ovaries but do not respond well to standard ovarian stimulation by Gonadotropin (known as POSEIDON Group 1a). The main questions it aims to answer are: How many mature oocytes can be obtain after biphasic -VM? Researchers will use biphasic-IVM system to see if it can bypass the problems these patients face with standard treatments, such as high costs and the risk of medical complications like Ovarian Hyperstimulation Syndrome (OHSS). Participants will: Have their immature eggs collected from the ovaries without the need for high-dose hormone injections. Have their eggs matured in a specialized laboratory using a two-step process (biphasic IVM) to improve egg quality. Follow up with researchers to check the number of embryos created and the safety of the procedure.
Eligibility Criteria
Inclusion Criteria: * Women aged 18 - \< 35 years * At least one IVF cycle have been failed and classified as having a poor response to POSEIDON group Ia. * POSEIDON group Ia ( \< 35 age; AMH \>= 1.2 ng/ml and/or AFC \>=5 antral follicles; have \< 4 oocytes was retrieved at previous IVF cycle) * Agree to apply biphasic-IVM treatment. * Agree to freeze all embryos and to transfer the frozen embryos afterward. * Agree to participate in the study. Exclusion Criteria: * Egg-donation cycle * Uterine abnormalities: adenomyosis, large uterine fibroids (≥5 cm), bicornuate uterus, uterine adhesions. * Sperm surgical (PESA, TESE, mTESE) * PGT
Contact & Investigator
Ho L. Le, MD
PRINCIPAL INVESTIGATOR
Frequently Asked Questions
Who can join the NCT07632300 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 35 Years, studying Healthy Adult Females. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07632300 currently recruiting?
Yes, NCT07632300 is actively recruiting participants. Contact the research team at bsho.ll@myduchospital.vn for enrollment information.
Where is the NCT07632300 trial being conducted?
This trial is being conducted at Ho Chi Minh City, Vietnam.
Who is sponsoring the NCT07632300 clinical trial?
NCT07632300 is sponsored by Mỹ Đức Hospital. The principal investigator is Ho L. Le, MD. The trial plans to enroll 25 participants.